Kanneboyina Nagaraju

Kanneboyina Nagaraju

Auto-generated profile, based on publicly available information

Kanneboyina Nagaraju

Affiliations AGADA Biosciences Inc., Halifax, Nova Scotia, Canada, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, State University of New York, New York, United States of America

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2011 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
CSChristopher Spurney
Christopher Spurney
ASArpana Sali
Arpana Sali
Alfredo Daniel GuerronAlfredo Daniel Guerron
Alfredo Daniel Guerron
MIMicaela Iantorno
Micaela Iantorno
QYQing Yu
Qing Yu
KNKanneboyina Nagaraju
Kanneboyina Nagaraju
Recent studies showed that chronic administration of losartan, an angiotensin II type I receptor antagonist, improved skeletal muscle function in dystrophin-deficient mdx mice. In this study, C57BL/10ScSn-Dmdmdx/J female mice were either untreated or treated with losartan (n = 15) in the drinking water at a dose of 600 mg/L over a 6-month period. Cardiac function was assessed via in vivo high frequency echocardiography and skeletal muscle function was assessed using grip strength testing, Digiscan monitoring, Rotarod timing, and in vitro force testing. Fibrosis was assessed using picrosirius red staining and Image J analysis. Gene expression was evaluated using real-time polymerized chain reaction (RT-PCR). Percentage shortening fraction was significantly decreased in untreated (26.9% ± 3.5%) mice compared to losartan-treated (32.2% ± 4.2%; P < .01) mice. Systolic blood pressure was significantly reduced in losartan-treated mice (56 ± 6 vs 69 ± 7 mm Hg; P < .0005). Percentage cardiac fibrosis was significantly reduced in losartan-treated hearts (P < .05) along with diaphragm (P < .01), extensor digitorum longus (P < .05), and gastrocnemius (P < .05) muscles compared to untreated mdx mice. There were no significant differences in skeletal muscle function between treated and untreated groups. Chronic treatment with losartan decreases cardiac and skeletal muscle fibrosis and improves cardiac systolic function in dystrophin-deficient mdx mice.

11 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XLXu Liu
Xu Liu
YWYashuo Wang
Yashuo Wang
JGJennifer S. Gutierrez
Jennifer S. Gutierrez
JDJesse M. Damsker
Jesse M. Damsker
KNKanneboyina Nagaraju
Kanneboyina Nagaraju
EOEric A. Ortlund
Eric A. Ortlund
Significance: Corticosteroids that are currently in clinical use bind to the glucocorticoid receptor (GR) to exert antiinflammation effects, yet are associated with undesirable side effects. Vamorolone is a recently developed drug for Duchenne muscular dystrophy; it decreases muscle inflammation and reduces side effects observed in other corticosteroid-based treatments. Our structure studies reveal a crucial GR-ligand hydrogen bond is not possible in vamorolone. An unprecedented allosteric intramolecular network derived from this hydrogen bond modulates GR dynamic motions and coregulator binding. Our work provides insights into how subtle modifications on a drug exploits structural and dynamic properties in the receptor to dissociate downstream side effects from therapeutic benefits.

3 January 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RCRoberta Francesca Capogrosso
Roberta Francesca Capogrosso
PMPaola Mantuano
Paola Mantuano
KUKitipong Uaesoontrachoon
Kitipong Uaesoontrachoon
ACAnna Cozzoli
Anna Cozzoli
AGArcangela Giustino
Arcangela Giustino
ALAnnamaria De Luca
Annamaria De Luca
Muscle fibers lacking dystrophin undergo a long‐term alteration of Ca 2+ homeostasis, partially caused by aleaky Ca 2+ release ryanodine (RyR) channel. S48168/ARM210, an RyR calcium release channel stabilizer (a Rycal compound), is expected to enhance the rebinding of calstabin to the RyR channel complex and possibly alleviate the pathologic Ca 2+ leakage in dystrophin‐deficient skeletal and cardiac muscle. This study systematically investigated the effect of S48168/ARM210 on the phenotype of mdx mice by means of a first proof‐of‐concept, short (4 wk), phase 1 treatment, followed by a 12‐wk treatment (phase 2) performed in parallel by 2 independent laboratories. The mdx mice were treated with S48168/ARM210 at two different concentrations (50 or 10 mg/kg/d) in their drinking water for 4 and 12 wk, respectively. The mice were subjected to treadmill sessions twice per week (12 m/min for 30 min) to unmask the mild disease. This testing was followed by in vivo forelimb and hindlimb grip strength and fatigability measurement, ex vivo extensor digitorum longus (EDL) and diaphragm (DIA) force contraction measurement and histologic and biochemical analysis. The treatments resulted in functional (grip strength, ex vivo force production in DIA and EDL muscles) as well as histologic improvement after 4 and 12 wk, with no adverse effects. Furthermore, levels of cellular biomarkers of calcium homeostasis increased. Therefore, these data suggest that S48168/ARM210 may be a safe therapeutic option, at the dose levels tested, for the treatment of Duchenne muscular dystrophy (DMD).—Capogrosso, R. F., Mantuano, P., Uaesoontrachoon, K., Cozzoli, A., Giustino, A., Dow, T., Srinivassane, S., Filipovic, M., Bell, C., Vandermeulen, J., Massari, A. M., De Bellis, M., Conte, E., Pierno, S., Camerino, G. M., Liantonio, A., Nagaraju, K., De Luca, A. Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin‐deficient mdx mice: proof‐of‐concept study and independent validation of efficacy. FASEB J. 32, 1025–1043 (2018). www.fasebj.org

22 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JBJessica F. Boehler
Jessica F. Boehler
MHMarshall W. Hogarth
Marshall W. Hogarth
MBMatthew D. Barberio
Matthew D. Barberio
JNJames S. Novak
James S. Novak
SGSvetlana Ghimbovschi
Svetlana Ghimbovschi
KNKanneboyina Nagaraju
Kanneboyina Nagaraju
To identify changes in skeletal muscle microRNA expression after endurance exercise and associate the identified microRNAs with mRNA and protein expression to disease-specific pathways in polymyositis (PM) and dermatomyositis (DM) patients. Following a parallel clinical trial design, patients with probable PM or DM, exercising less than once a week, and on stable medication for at least one month were randomized into two groups at Karolinska University Hospital: a 12-week endurance exercise group (n = 12) or a non-exercised control group (n = 11). Using an Affymetrix microarray, microRNA expression was determined in paired muscle biopsies taken before and after the exercise intervention from 3 patients in each group. Ingenuity pathway analysis with a microRNA target filter was used to identify microRNA transcript targets. These targets were investigated at the mRNA (microarray) and protein (mass spectrometry) levels in patients. Endurance exercise altered 39 microRNAs. The microRNAs with increased expression were predicted to target transcripts involved in inflammatory processes, metabolism, and muscle atrophy. Further, these target transcripts had an associated decrease in mRNA expression in exercised patients. In particular, a decrease in the NF-κB regulator IKBKB was associated with an increase in its target microRNA (miR-196b). At the protein level, there was an increase in mitochondrial proteins (AK3, HIBADH), which were associated with a decrease in microRNAs that were predicted to regulate their expression. Improvement in disease phenotype after exercise is associated with increasing microRNAs that target and downregulate immune processes at the transcript level, as well as decreasing microRNAs that target and upregulate mitochondrial content at the protein level. Therefore, microRNAs may improve disease by decreasing immune responses and increasing mitochondrial biogenesis. ClinicalTrials.gov NCT01184625

18 July 2019 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
JBJessica F Boehler
Jessica F Boehler
AHAdam Horn
Adam Horn
JNJames S Novak
James S Novak
NLNing Li
Ning Li
SGSvetlana Ghimbovschi
Svetlana Ghimbovschi
KNKanneboyina Nagaraju
Kanneboyina Nagaraju

3 February 2020 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
TKTravis B. Kinder
Travis B. Kinder
CHChristopher R. Heier
Christopher R. Heier
CTChristopher B. Tully
Christopher B. Tully
JMJack H. Van der Muelen
Jack H. Van der Muelen
Eric P HoffmanEric P Hoffman
Eric P Hoffman
AFAlyson A. Fiorillo
Alyson A. Fiorillo
Objective: Muscle inflammation is a feature in myositis and Duchenne muscular dystrophy (DMD). Autoimmune mechanisms are thought to contribute to muscle weakness in patients with myositis. However, a lack of correlation between the extent of inflammatory cell infiltration and muscle weakness indicates that nonimmune pathologic mechanisms may play a role. The present study focused on 2 microRNA (miRNA) sets previously identified as being elevated in the muscle of patients with DMD—an “inflammatory” miRNA set that is dampened with glucocorticoids, and a “dystrophin‐targeting” miRNA set that inhibits dystrophin translation—to test the hypothesis that these miRNAs are similarly dysregulated in the muscle of patients with myositis, and could contribute to muscle weakness and disease severity.Methods: A major histocompatibility complex class I–transgenic mouse model of myositis was utilized to study gene and miRNA expression and histologic features in the muscle tissue, with the findings validated in human muscle biopsy tissue from 6 patients with myositis. Mice were classified as having mild or severe myositis based on transgene expression, body weight, histologic disease severity, and muscle strength/weakness.Results: In mice with severe myositis, muscle tissue showed mononuclear cell infiltration along with elevated expression of type I interferon and NF‐κB–regulated genes, including Tlr7 (3.8‐fold increase, P < 0.05). Furthermore, mice with severe myositis showed elevated expression of inflammatory miRNAs (miR‐146a, miR‐142‐3p, miR‐142‐5p, miR‐455‐3p, and miR‐455‐5p; ~3–40‐fold increase, P < 0.05) and dystrophin‐targeting miRNAs (miR‐146a, miR‐146b, miR‐31, and miR‐223; ~3–38‐fold increase, P < 0.05). Bioinformatics analyses of chromatin immunoprecipitation sequencing (ChIP‐seq) data identified at least one NF‐κB consensus element within the promoter/enhancer regions of these miRNAs. Western blotting and immunofluorescence analyses of the muscle tissue from mice with severe myositis demonstrated reduced levels of dystrophin. In addition, elevated levels of NF‐κB–regulated genes, TLR7, and miRNAs along with reduced dystrophin levels were observed in muscle biopsy tissue from patients with histologically severe myositis.Conclusion: These data demonstrate that an acquired dystrophin deficiency may occur through NF‐κB–regulated miRNAs in myositis, thereby suggesting a unifying theme in which muscle injury, inflammation, and weakness are perpetuated both in myositis and in DMD.